Tag: Anca vasculitis

The incidence of hydralazine-induced ANCA vasculitis is dose-dependent, rising from 5.4% in patients taking 100 mg/day to 10.4% for those on 200 mg/day for over three years [1.7.2]. So, what are the symptoms of hydralazine induced vasculitis to watch for?

ANCA-associated vasculitis (AAV) historically had a high mortality rate, but modern immunosuppressive therapies have transformed it into a manageable chronic condition. While a cure is not yet possible, the primary goal of treatment is to induce and maintain remission, preventing relapse and irreversible organ damage. The best treatment for ANCA vasculitis depends on disease severity and patient-specific factors, incorporating new targeted agents alongside established protocols.

Drug-induced vasculitis accounts for about 10% of all vasculitis cases, and certain blood pressure medications are among the known triggers [1.2.1]. While rare, the question of **'Can blood pressure medicine cause vasculitis?'** is critical for patient awareness and safety.

Drug-induced vasculitis accounts for up to 30% of cutaneous vasculitis cases, highlighting the need for vigilance when assessing a patient's medication history. Identifying what drugs cause vasculitis is critical, as this inflammatory condition of the blood vessels can range from mild skin rashes to life-threatening multiorgan damage.

Drug-induced leukocytoclastic vasculitis (LCV), a common form of drug-related vasculitis, accounts for approximately 10% of all vasculitis cases [1.4.3]. Understanding **what drugs trigger vasculitis** is crucial for both patients and healthcare providers to recognize and manage this serious condition.

Drug-induced vasculitis accounts for approximately 3% of all vasculitis cases [1.2.1]. This condition involves inflammation of blood vessels triggered by certain medications. Understanding **which drugs cause vasculitis** is the first step toward diagnosis and management.

Drug-induced ANCA-associated vasculitis (AAV) is a recognized adverse effect of certain medications, with some case series highlighting its association with specific drugs like propylthiouracil and hydralazine. This condition involves inflammation of small blood vessels and is clinically and serologically similar to primary AAV.

While omeprazole is widely used and generally well-tolerated, adverse drug reactions affect up to 5% of patients. Among these, rare case reports and studies have established a link, suggesting that **can omeprazole cause vasculitis** in some individuals as a rare hypersensitivity response.